Springfield, ORNCT07558733Now EnrollingIRB Ready

HR+ HER2- Breast Cancer Clinical Trial in Springfield, OR

Access cutting-edge hr+ her2- breast cancer treatment through this clinical trial at a research site in Springfield. Study-provided care at no cost to qualified participants.

Sponsored by Faeth Therapeutics

Quick Self-Assessment

See if you qualify for this Springfield location

Preparing your pre-screening questions…

Expert Care in Springfield

Access hr+ her2- breast cancer specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related hr+ her2- breast cancer treatment provided free

Apply for This Springfield Location

Check if you qualify for this hr+ her2- breast cancer clinical trial in Springfield, OR

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Springfield

    Convenient for OR residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Springfield site if eligible
  4. 4Begin participation

About This HR+ HER2- Breast Cancer Study in Springfield

The study is a Phase 1b/2, multi-center, open-label, dose escalation trial evaluating the safety and preliminary efficacy of sapanisertib and serabelisib (PIKTOR) with fulvestrant and/or other anticancer therapies in participants with HR+/HER2- advanced/metastatic breast cancer.

Sponsor: Faeth Therapeutics

Who Can Participate

Inclusion Criteria

Histologically confirmed diagnosis of HR+/HER2- breast cancer.
Documented evidence of advanced or recurrent disease that is not amenable to surgery/radiation for curative intent.
Participant has received at least one prior systemic therapy.
At least 1 measurable or evaluable target lesion according to RECIST v1.1
Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1 at Screening.
Non-pregnant, non-lactating females who are postmenopausal, surgically sterile or who agree to use effective contraceptive methods.

Exclusion Criteria

Participants with triple-negative breast cancer.
Participants with central nervous system metastases are not eligible, unless they have completed local therapy and have discontinued the use of corticosteroids for this indication for at least 4 weeks before starting treatment in this study.
Active malignancy (except for breast cancer, definitively treated in-situ carcinomas \[e.g., breast, cervix, bladder\], or basal or squamous cell carcinoma of the skin) within the past 24 months prior to treatment. Fully resected localized malignancies are eligible.
Gastric feeding tube (gastrostomy tube), gastrointestinal malabsorption, gastrointestinal anastomosis, bowel obstruction, or any other condition that might affect the absorption of study treatment.
Significant cardiovascular impairment.
Active, uncontrolled infection.
Concurrent participation in another therapeutic clinical trial.
Prior radiation therapy within 21 days prior to start of study treatment.
Participants who have received a prior PI3K, AKT, mTORC1/2, or dual PI3K/mTOR inhibitor.
Strong CYP3A4 inhibitors, strong CYP1A2 inhibitors or CYP1A2 inducers, or clinically significant CYP3A4 inducers within 7 days before the first dose of study intervention, or participants who require treatment with strong CYP3A4 inhibitors or inducers during the study.
Prolongation of QTc interval to \>480 ms.
Type 1 or Type 2 diabetes mellitus on insulin.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Springfield?

Yes, this clinical trial (NCT07558733) has an active research site in Springfield, OR that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

HR+ HER2- Breast Cancer Treatment Options in Springfield, OR

If you're searching for hr+ her2- breast cancer treatment options in Springfield, OR, this clinical trial (NCT07558733) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Springfield research site is actively enrolling participants for this clinical trial. You'll receive care from experienced hr+ her2- breast cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all hr+ her2- breast cancer clinical trials near you to find additional studies recruiting in your area.

More Breast Cancer Trials in Springfield, OR

See all breast cancer clinical trials recruiting in Springfield — not just this study.

Browse Breast Cancer Trials in Springfield →

Browse More Trials by Condition

Breast Cancer TrialsAnkylosing Spondylitis TrialsAll Conditions →

Ready to Join in Springfield?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Springfield, OR